|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Uptravi
|
|
gptkbp:activities
|
selective prostacyclin receptor agonist
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2015
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Uptravi
|
|
gptkbp:category
|
gptkb:unknown
Category B
|
|
gptkbp:clinical_trial
|
Phase III
treatment of pulmonary arterial hypertension
|
|
gptkbp:contraindication
|
severe hepatic impairment
|
|
gptkbp:developed_by
|
gptkb:Actelion_Pharmaceuticals
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
selexipag
|
|
gptkbp:ingredients
|
C22 H26 O5 S
|
|
gptkbp:interacts_with
|
anticoagulants
antihypertensives
diuretics
NSAI Ds
|
|
gptkbp:is_atype_of
|
C02 K X01
|
|
gptkbp:is_used_for
|
pulmonary arterial hypertension
|
|
gptkbp:lifespan
|
5 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:name
|
Essential Medicines
|
|
gptkbp:pharmacokinetics
|
vasodilation
oral bioavailability 100%
|
|
gptkbp:side_effect
|
headache
muscle pain
nausea
diarrhea
jaw pain
|
|
gptkbp:traded_on
|
gptkb:Uptravi
|
|
gptkbp:type_of
|
1195760-78-6
|